SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla gains on launching therapy for Knee Osteoarthritis ‘Ciplostem’

04 Dec 2025 Evaluate

Cipla is currently trading at Rs 1511.25, up by 3.15 points or 0.21% from its previous closing of Rs 1508.10 on the BSE.

The scrip opened at Rs 1502.40 and has touched a high and low of Rs 1511.25 and Rs 1502.40 respectively. So far 6335 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 2 has touched a 52-week high of Rs 1672.20 on 23-Oct-2025 and a 52-week low of Rs 1310.05 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs 1536.20 and Rs 1495.95 respectively. The current market cap of the company is Rs 121949.22 crore.

The promoters holding in the company stood at 29.21%, while Institutions and Non-Institutions held 54.79% and 16.00% respectively.

Cipla has partnered with Stempeutics Research to launch Ciplostem, a therapy for Knee Osteoarthritis, approved by the Drug Controller General of India (DCGI). Developed by Stempeutics Research, the therapy offers a disease-modifying treatment option targeting Grade II and III Knee OA and marks a significant advancement in Cipla's entry into Orthobiologic medicine. 

Through this launch, Cipla and Stempeutics reaffirm their collective focus on science- driven progress in chronic disease management, offering a next-generation joint preservation therapy aimed at improving patients’ everyday lives.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1238.30 7.55 (0.61%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×